fbpx

CooperVision Introduces MyDay® Toric Daily Disposables in Canada

CooperVision, Inc. announced today the introduction of MyDay® toric daily disposable contact lenses in Canada. MyDay® toric offers an extensive power range in a 1 day toric silicone hydrogel lens.

MyDay® toric features the same Optimized Toric Lens Geometry found in Biofinity® toric. It provides a uniform horizontal ISO thickness, an optimized ballast band design, large toric optic zone, and a smooth, continuous surface to make it an easy-to-fit, stable toric lens.

The MyDay® family of lenses is naturally wettable, without coatings or surface treatments. It also offers built-in UV protection that filters 85% of UVA and 96% of UVB rays** to help promote long-term ocular health.

By using less silicon, MyDay® has more room in the lens for hydrophilic (water loving) material, resulting in improved surface wettability, higher water content, and lower modulus for a softer, more comfortable lens-wearing experience. It also enables a modulus of only 0.4 MPa to make MyDay® CooperVision’s softest ever 1 day silicone hydrogel contact lens.

Guy Whittaker, Senior Vice President of Global Marketing at CooperVision, says, “MyDay® toric is an advanced lens that practitioners can use to help further build their practices by giving patients with astigmatism a soft, comfortable lens-wearing experience with the lens stability and visual acuity they have come to expect from CooperVision’s toric lenses.”

MyDay® toric further expands CooperVision’s 1 day portfolio, with practitioners able to select from the MyDay®, clariti® 1 day and Proclear® families of 1 day lenses to provide exceptional options for just about every eye.

The complete range of MyDay® toric lenses is currently available in sphere powers from Plano to   -6.00 (0.25D steps), -6.00 to -10.00 and Plano to +6.00 (0.50D steps) (plus powers available in 2018); cylinder options of -0.75, -1.25, and -1.75 in axes of 10°, 20°, 70°, 80°, 90°, 100°, 110°, 160°, 170°, and 180°; and -2.25 cylinder in axes of 10°, 20°, 90°, 160°, 170°, and 180°. MyDay® toric lenses have a base curve of 8.6 mm and a diameter of 14.5 mm.

Click HERE for the full press release.

 

Featured Posts

Optometry Giving Sight logo a turquoise eye with black icons in the shape of people for the iris

Optometry Giving Sight Announces 2024 Grant Winners

This year, 16 grants totaling almost $1 million USD have been awarded to 15 organizations for projects that will help eradicate uncorrected refractive error globally.

Learn More
Fighting Blindness Canada research

Gene Therapy for Wet AMD: Phase 1/2 Clinical Trial Results

A new study published in The Lancet shared results from a Phase 1/2 clinical trial testing a one-time anti-VEGF gene therapy for wet age-related macular degeneration (wet AMD).

Read more
CooperVision

CooperVision Hosts Canadian ECPs for Innovation Tour in Costa Rica

CooperVision recently hosted an Innovation Tour for 20 eye care professionals from across Canada at its state-of-the-art, LEED® certified manufacturing facility located in San José, Costa Rica.

Read more
The Centre for Eye and Vision Research (CEVR) and SCOPE Health Inc. logos

CEVR and SCOPE Health Sign a MoU to Develop and Commercialize Novel Product Technologies for the Treatment of Dry Eye and Ocular Surface Conditions

The Centre for Eye and Vision Research (CEVR) and SCOPE Health Inc. have announced the signing of a Memorandum of Understanding (MoU) to establish a collaborative partnership focused on developing innovative technologies for dry eye disease and other ocular surface conditions.

Read more
SightGlass Vision

Three New Peer Reviewed Papers Expand Myopia Management Evidence for SightGlass Vision Diffusion Optics Technology™

Works in BMJ Open Ophthalmology, Ophthalmic and Physiological Optics, and Translational Vision Science & Technology Focus on Efficacy, Vision, and Contrast Theory

Read more
Optometry Giving Sight logo a turquoise eye with black icons in the shape of people for the iris

Optometry Giving Sight Announces 2024 Grant Winners

This year, 16 grants totaling almost $1 million USD have been awarded to 15 organizations for projects that will help eradicate uncorrected refractive error globally.

Learn More
Fighting Blindness Canada research

Gene Therapy for Wet AMD: Phase 1/2 Clinical Trial Results

A new study published in The Lancet shared results from a Phase 1/2 clinical trial testing a one-time anti-VEGF gene therapy for wet age-related macular degeneration (wet AMD).

Read More
CooperVision

CooperVision Hosts Canadian ECPs for Innovation Tour in Costa Rica

CooperVision recently hosted an Innovation Tour for 20 eye care professionals from across Canada at its state-of-the-art, LEED® certified manufacturing facility located in San José, Costa Rica.

Read More
The Centre for Eye and Vision Research (CEVR) and SCOPE Health Inc. logos

CEVR and SCOPE Health Sign a MoU to Develop and Commercialize Novel Product Technologies for the Treatment of Dry Eye and Ocular Surface Conditions

The Centre for Eye and Vision Research (CEVR) and SCOPE Health Inc. have announced the signing of a Memorandum of Understanding (MoU) to establish a collaborative partnership focused on developing innovative technologies for dry eye disease and other ocular surface conditions.

Read More
SightGlass Vision

Three New Peer Reviewed Papers Expand Myopia Management Evidence for SightGlass Vision Diffusion Optics Technology™

Works in BMJ Open Ophthalmology, Ophthalmic and Physiological Optics, and Translational Vision Science & Technology Focus on Efficacy, Vision, and Contrast Theory

Read More
Optometry Giving Sight logo a turquoise eye with black icons in the shape of people for the iris

Optometry Giving Sight Announces 2024 Grant Winners

This year, 16 grants totaling almost $1 million USD have been awarded to 15 organizations for projects that will help eradicate uncorrected refractive error globally.

Learn More
Fighting Blindness Canada research

Gene Therapy for Wet AMD: Phase 1/2 Clinical Trial Results

A new study published in The Lancet shared results from a Phase 1/2 clinical trial testing a one-time anti-VEGF gene therapy for wet age-related macular degeneration (wet AMD).

Read more
CooperVision

CooperVision Hosts Canadian ECPs for Innovation Tour in Costa Rica

CooperVision recently hosted an Innovation Tour for 20 eye care professionals from across Canada at its state-of-the-art, LEED® certified manufacturing facility located in San José, Costa Rica.

Read more
The Centre for Eye and Vision Research (CEVR) and SCOPE Health Inc. logos

CEVR and SCOPE Health Sign a MoU to Develop and Commercialize Novel Product Technologies for the Treatment of Dry Eye and Ocular Surface Conditions

The Centre for Eye and Vision Research (CEVR) and SCOPE Health Inc. have announced the signing of a Memorandum of Understanding (MoU) to establish a collaborative partnership focused on developing innovative technologies for dry eye disease and other ocular surface conditions.

Read more
SightGlass Vision

Three New Peer Reviewed Papers Expand Myopia Management Evidence for SightGlass Vision Diffusion Optics Technology™

Works in BMJ Open Ophthalmology, Ophthalmic and Physiological Optics, and Translational Vision Science & Technology Focus on Efficacy, Vision, and Contrast Theory

Read more
Optometry Giving Sight logo a turquoise eye with black icons in the shape of people for the iris

Optometry Giving Sight Announces 2024 Grant Winners

This year, 16 grants totaling almost $1 million USD have been awarded to 15 organizations for projects that will help eradicate uncorrected refractive error globally.

Learn More
Fighting Blindness Canada research

Gene Therapy for Wet AMD: Phase 1/2 Clinical Trial Results

A new study published in The Lancet shared results from a Phase 1/2 clinical trial testing a one-time anti-VEGF gene therapy for wet age-related macular degeneration (wet AMD).

Read more
CooperVision

CooperVision Hosts Canadian ECPs for Innovation Tour in Costa Rica

CooperVision recently hosted an Innovation Tour for 20 eye care professionals from across Canada at its state-of-the-art, LEED® certified manufacturing facility located in San José, Costa Rica.

Read more
The Centre for Eye and Vision Research (CEVR) and SCOPE Health Inc. logos

CEVR and SCOPE Health Sign a MoU to Develop and Commercialize Novel Product Technologies for the Treatment of Dry Eye and Ocular Surface Conditions

The Centre for Eye and Vision Research (CEVR) and SCOPE Health Inc. have announced the signing of a Memorandum of Understanding (MoU) to establish a collaborative partnership focused on developing innovative technologies for dry eye disease and other ocular surface conditions.

Read more
SightGlass Vision

Three New Peer Reviewed Papers Expand Myopia Management Evidence for SightGlass Vision Diffusion Optics Technology™

Works in BMJ Open Ophthalmology, Ophthalmic and Physiological Optics, and Translational Vision Science & Technology Focus on Efficacy, Vision, and Contrast Theory

Read more